BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11191144)

  • 1. Age, sex, haemoglobin level, and white cell count at diagnosis are important prognostic factors in children with acute lymphoblastic leukemia treated with BFM-type protocol.
    Ng SM; Lin HP; Ariffin WA; Zainab AK; Lam SK; Chan LL
    J Trop Pediatr; 2000 Dec; 46(6):338-43. PubMed ID: 11191144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features and treatment outcome of children with myeloid antigen coexpression in B-lineage acute lymphoblastic leukemia: a study of 151 Malaysian children.
    Ng SM; Ariffin WA; Lin HP; Chan LL; Chin YM
    J Trop Pediatr; 2000 Apr; 46(2):73-8. PubMed ID: 10822932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors in adolescent and adult patients with acute lymphoblastic leukemia with two protocols of chemotherapy: a cross-sectional study.
    Pinheiro Junior ED; Pracchia LF; Beitler de Mauriño B; Martinez GA; Dorlhiac-Llacer PE; Medina AB; Velloso ED
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):e7-e14. PubMed ID: 25130688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis Of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE).
    Donadieu J; Auclerc MF; Baruchel A; Perel Y; Bordigoni P; Landman-Parker J; Leblanc T; Cornu G; Sommelet D; Leverger G; Schaison G; Hill C;
    Br J Cancer; 2000 Dec; 83(12):1617-22. PubMed ID: 11104555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience].
    Badowska W
    Med Wieku Rozwoj; 2008; 12(4 Pt 2):1001-7. PubMed ID: 19531816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Twenty years of treating childhood acute lymphoblastic leukemia].
    Pérez Martínez A; Alonso Ojembarrena A; Ramírez Orellana M; García Castro J; González-Vicent M; Contra Gómez T; Madero López L; Díaz Pérez MA
    An Pediatr (Barc); 2006 Sep; 65(3):198-204. PubMed ID: 16956497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Childhood acute lymphoblastic leukemia: prognostic value of initial peripheral blast count in good responders to prednisone.
    Felice MS; Zubizarreta PA; Alfaro EM; Sackmann-Muriel F
    J Pediatr Hematol Oncol; 2001 Oct; 23(7):411-5. PubMed ID: 11878573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).
    Kamps WA; Bökkerink JP; Hakvoort-Cammel FG; Veerman AJ; Weening RS; van Wering ER; van Weerden JF; Hermans J; Slater R; van den Berg E; Kroes WG; van der Does-van den Berg A
    Leukemia; 2002 Jun; 16(6):1099-111. PubMed ID: 12040440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
    Attarbaschi A; Mann G; Dworzak M; Urban C; Fink FM; Dieckmann K; Riehm H; Gadner H;
    Wien Klin Wochenschr; 2002 Feb; 114(4):148-57. PubMed ID: 12060981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcome of adolescents with acute lymphoblastic leukemia.
    Irken G; Oren H; Gülen H; Duman M; Uçar C; Atabay B; Yilmaz S; Uysal K; Cevik N
    Ann Hematol; 2002 Nov; 81(11):641-5. PubMed ID: 12454702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.
    Conter V; Schrappe M; Aricó M; Reiter A; Rizzari C; Dördelmann M; Valsecchi MG; Zimmermann M; Ludwig WD; Basso G; Masera G; Riehm H
    J Clin Oncol; 1997 Aug; 15(8):2786-91. PubMed ID: 9256120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
    Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
    J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Outcome of childhood high-risk acute lymphoblastic leukemia treated with the ALL-BFM 95 protocol].
    Ruan YS; Wu XD; Feng XQ; He YL; Zhang YM; Pei FY; Li CF
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Apr; 17(4):327-31. PubMed ID: 25919549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P.
    Gaynon PS; Bleyer WA; Steinherz PG; Finklestein JZ; Littman PS; Miller DR; Reaman GH; Sather HN; Hammond GD
    Am J Pediatr Hematol Oncol; 1988; 10(1):42-50. PubMed ID: 3056061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group.
    Veerman AJ; Hählen K; Kamps WA; Van Leeuwen EF; De Vaan GA; Solbu G; Suciu S; Van Wering ER; Van der Does-Van der Berg A
    J Clin Oncol; 1996 Mar; 14(3):911-8. PubMed ID: 8622039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
    Manabe A; Ohara A; Hasegawa D; Koh K; Saito T; Kiyokawa N; Kikuchi A; Takahashi H; Ikuta K; Hayashi Y; Hanada R; Tsuchida M;
    Haematologica; 2008 Aug; 93(8):1155-60. PubMed ID: 18519521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.